PROTEIN KINASE DEFICIENT, IMMUNOLOGICALLY ACTIVE CMVpp65 MUTANT CELLULAR VACCINES

Abstract

This invention relates to mutated CMVpp65, a viral structural protein which activates cell mediated immunity in humans infected with CMV. The mutations remove undesirable protein kinase activity naturally present in the protein and make it suitable for the production of both DNA and protein vaccines. Therefore, the invention provides proteins and DNAs, as well as vaccines comprising the proteins and DNAs, including cellular vaccines and vectors. Other embodiments related to the invention are methods of enhancing immune response and vaccinating against CMV, including gene therapy methods and vectors.

1 . A cellular vaccine which expresses a mutant cytomegalovirus pp65 protein that lacks protein kinase activity and that when administered to a mammal elicits a CTL immune response against cells infected with cytomegalovirus, wherein said cytomegalovirus pp65 protein contains a site-specific mutation at amino acid 436 or at both amino acid 436 and amino acid 465. 
     
     
         2 . A cellular vaccine of  claim 1  wherein said cytomegalovirus pp65 protein contains the K436N mutation. 
     
     
         3 . A cellular vaccine composition which comprises (1) an antigen presenting cell that has been treated in vitro so as to present epitopes of a mutant cytomegalovirus pp65 protein that lacks protein kinase activity and that when administered to a mammal elicits a CTL immune response against cells infected with cytomegalovirus, wherein said cytomegalovirus pp65 protein contains a site-specific mutation at amino acid 436 or at both amino acid 436 and amino acid 465, and (2) a pharmaceutically acceptable carrier.